SLXN SILEXION THERAPEUTICS CORP

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City.

Silexion's company presentation will take place on Tuesday, September 10, 2025, at 2:00 PM ET. An updated company presentation has been posted to Silexion's website in the Presentation & Events section of the Company’s investor site.

The Silexion management team will be available for in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with Silexion through their H.C. Wainwright representative or e-mail



About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.



Contacts

Company Contact:

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO

Capital Markets & IR Contact:

Arx Capital Markets

North American Equities Desk



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SILEXION THERAPEUTICS CORP

 PRESS RELEASE

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requireme...

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital Market GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Comp...

 PRESS RELEASE

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offerin...

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of  1,500,000 of the Company’s ordinary shares (or ordinary share equivalents), series A warrants to purchase up to  1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shares at a combined publ...

 PRESS RELEASE

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating ...

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further Validation of the Systemic Component of a Dual-Route Administration Strategy Enabeling Potential Targeting of Both Primary Tumors and Metastatic Disease  Silexion Remains on Track for Phase 2/3 Trial Initiation in H1 2026 Follow...

 PRESS RELEASE

Silexion Therapeutics Announces Selection of Contract Research Organiz...

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204 Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and Q1 2026 Regulatory Submissions CRO Brings Over 28 Years of Drug Development Experience and Proven Phase 3 Oncology Trial Expertise to Support Upcoming Trial GRAND CAYMAN, Cayman Islands, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Silexion Therape...

 PRESS RELEASE

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wain...

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that senior management will be presenting at the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-10, 2025, at the Lotte New York Palace Hotel, New York City. Silexion's company presentation will...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch